Nippon Shokubai Co Ltd held a ground-breaking ceremony on, for the construction of a facility of active pharmaceutical ingredient (API) synthesis. The construction will be completed in December 2018.
Purpose of investment
In the current long-term business plan “Reborn Nippon Shokubai 2020” started in 2014 and the 2nd medium-term Business Plan “Reborn Nippon Shokubai 2020 NEXT” started in 2017, Nippon Shokubai has a plan to open up a health and medical business field as one of the new business domains. Targeting the peptide drugs, nucleic-acid drugs and DDS where market growth is expected, Nippon Shokubai is establishing a drug development support business that provides customers a consistent service from drug discovery & clinical studies to contract manufacturing.
In order to establish a business base on these promising areas, Nippon Shokubai keeps on not only seeking out chances of business partnerships with innovative technical resources outside the company but also studying a feasibility of establishing function of manufacturing these kinds of APIs.
No comments:
Post a Comment